Bay 59-7939/17454: An International, Multicenter, Randomized, Double-Blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients with Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures. VOYAGER PAD Department of Pediatrics | College of Medicine – Jacksonville

Bay 59-7939/17454: An International, Multicenter, Randomized, Double-Blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients with Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures. VOYAGER PAD

Study Description

The purpose of this study is to find out about the safety and efficacy of rivaroxaban combined with aspirin in reducing the risk of major cardiovascular events (such as stroke or heart attack) after a person with vessel disease in their legs has had a revascularization procedure to improve blood flow.

Patients who qualify for this study will be assigned by chance (like the flip of a coin) to get one of the following treatments: • Treatment 1: Rivaroxaban 2.5mg tablet twice per day plus aspirin 100mg tablet once per day. • Treatment 2: Placebo tablet twice per day plus aspirin 100mg tablet once per day.

Investigators

Daniel Soffer, M.D.
Medicine